ProQR Therapeutics
PRQR
23 hedge funds and large institutions have $43.6M invested in ProQR Therapeutics in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 6 closing their positions.
9% more capital inflows, than outflows
Capital inflows: $6.35M | Capital outflows: $5.83M
0.84% more ownership
Funds ownership: 37.23% → 38.07% (+0.84%)
8% less funds holding
Funds holding: 25 → 23 (-2)
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Redmile Group
San Francisco,
California
|
+$5.16M |
| 2 |
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.03M |
| 3 |
Morgan Stanley
New York
|
+$93.8K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
+$33.1K |
| 5 |
Millennium Management
New York
|
+$13.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$3.34M |
| 2 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$1.71M |
| 3 |
Asset Management One
Tokyo,
Japan
|
-$255K |
| 4 |
Jennison Associates
New York
|
-$164K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$97.4K |
PRQR Hedge Fund Activity: Q4 2016 in Review
23 of the 4,008 institutional investors tracked by Wall St. Rank reported a position in ProQR Therapeutics (PRQR) for Q4 2016, worth a combined $43.6M — down 25% from $58M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of PRQR and 4 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 6 added.
The largest buyer was Redmile Group, adding an estimated $5.16M. The largest seller was Baker Bros. Advisors, cutting an estimated $3.34M.
- 23 institutional investors held ProQR Therapeutics (PRQR) as of Q4 2016, down from 25 in Q3 2016.
- Funds reported $43.6M of ProQR Therapeutics stock for Q4 2016, down 25% quarter-over-quarter.
- 4 funds opened new ProQR Therapeutics positions in Q4 2016 and 6 closed out, a net change of -2 holders.
- The largest ProQR Therapeutics buyer in Q4 2016 was Redmile Group, an estimated $5.16M added.
- The largest ProQR Therapeutics seller in Q4 2016 was Baker Bros. Advisors, an estimated $3.34M sold.
Based on aggregated 13F filings for Q4 2016.